Vivos Therapeutics, Inc.
VVOS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | -0.06 | 0.25 | -0.11 |
| FCF Yield | -9.62% | -14.85% | -15.50% | -12.29% |
| EV / EBITDA | -8.83 | -7.63 | -6.61 | -7.65 |
| Quality | ||||
| ROIC | -22.50% | -23.76% | -53.08% | -26.02% |
| Gross Margin | 58.04% | 55.24% | 50.03% | 56.71% |
| Cash Conversion Ratio | 0.77 | 0.70 | 0.98 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.09% | -2.33% | -3.42% | -1.73% |
| Free Cash Flow Growth | 23.38% | -12.36% | -22.25% | 21.91% |
| Safety | ||||
| Net Debt / EBITDA | -0.26 | -1.53 | 0.26 | 1.77 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -38.19 | -54.32 | -50.60 | -51.26 |